In the last three years, a subset of HCC patients in our center were treated with lenvatinib monotherapy, including some who were treated with lenvatinib-based combination treatment,such as lenvatinib plus PD-1 antibody and lenvatinib plus local treatment. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.